X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Orchid Chemicals with Cadila Healthcare - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ORCHID PHARMA LTD vs CADILA HEALTHCARE - Comparison Results

ORCHID PHARMA LTD    Change

Orchid Chemicals & Pharmaceuticals Ltd. (Orchid) is today a globally recognized, integrated pharmaceutical company with core competencies in the development and manufacture of Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms as well... More

CADILA HEALTHCARE 
   Change

Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ORCHID PHARMA LTD CADILA HEALTHCARE ORCHID PHARMA LTD/
CADILA HEALTHCARE
 
P/E (TTM) x -0.6 32.6 - View Chart
P/BV x 0.5 6.5 7.0% View Chart
Dividend Yield % 0.0 0.7 -  

Financials

 ORCHID PHARMA LTD   CADILA HEALTHCARE
EQUITY SHARE DATA
    ORCHID PHARMA LTD
Sep-13
CADILA HEALTHCARE
Mar-17
ORCHID PHARMA LTD/
CADILA HEALTHCARE
5-Yr Chart
Click to enlarge
High Rs194460 42.2%   
Low Rs35305 11.5%   
Sales per share (Unadj.) Rs276.592.1 300.2%  
Earnings per share (Unadj.) Rs-79.214.8 -534.6%  
Cash flow per share (Unadj.) Rs-43.518.5 -235.1%  
Dividends per share (Unadj.) Rs03.20 0.0%  
Dividend yield (eoy) %00.8 0.0%  
Book value per share (Unadj.) Rs53.968.0 79.3%  
Shares outstanding (eoy) m70.451,023.74 6.9%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x0.44.2 10.0%   
Avg P/E ratio x-1.425.8 -5.6%  
P/CF ratio (eoy) x-2.620.7 -12.7%  
Price / Book Value ratio x2.15.6 37.7%  
Dividend payout %021.6 0.0%   
Avg Mkt Cap Rs m8,067391,581 2.1%   
No. of employees `0002.816.9 16.6%   
Total wages/salary Rs m2,52715,002 16.8%   
Avg. sales/employee Rs Th6,956.15,594.5 124.3%   
Avg. wages/employee Rs Th902.5890.1 101.4%   
Avg. net profit/employee Rs Th-1,993.0899.9 -221.5%   
INCOME DATA
Net Sales Rs m19,47794,295 20.7%  
Other income Rs m4071,286 31.7%   
Total revenues Rs m19,88495,581 20.8%   
Gross profit Rs m1,10319,036 5.8%  
Depreciation Rs m2,5193,750 67.2%   
Interest Rs m5,227450 1,161.5%   
Profit before tax Rs m-6,23616,122 -38.7%   
Minority Interest Rs m20338 5.8%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m511-3 -17,033.3%   
Tax Rs m-1251,289 -9.7%   
Profit after tax Rs m-5,58015,168 -36.8%  
Gross profit margin %5.720.2 28.0%  
Effective tax rate %2.08.0 25.1%   
Net profit margin %-28.716.1 -178.1%  
BALANCE SHEET DATA
Current assets Rs m11,01460,223 18.3%   
Current liabilities Rs m32,06053,058 60.4%   
Net working cap to sales %-108.17.6 -1,422.1%  
Current ratio x0.31.1 30.3%  
Inventory Days Days9570 135.9%  
Debtors Days Days3488 38.1%  
Net fixed assets Rs m29,44072,984 40.3%   
Share capital Rs m7051,024 68.8%   
"Free" reserves Rs m2,04368,576 3.0%   
Net worth Rs m3,80069,600 5.5%   
Long term debt Rs m9,01824,684 36.5%   
Total assets Rs m46,510152,207 30.6%  
Interest coverage x-0.236.8 -0.5%   
Debt to equity ratio x2.40.4 669.2%  
Sales to assets ratio x0.40.6 67.6%   
Return on assets %-0.810.3 -7.4%  
Return on equity %-146.921.8 -673.9%  
Return on capital %-3.717.9 -20.8%  
Exports to sales %37.90-   
Imports to sales %22.60-   
Exports (fob) Rs m7,378NA-   
Imports (cif) Rs m4,406NA-   
Fx inflow Rs m7,51321,280 35.3%   
Fx outflow Rs m5,64910,874 51.9%   
Net fx Rs m1,86510,406 17.9%   
CASH FLOW
From Operations Rs m1,68213,495 12.5%  
From Investments Rs m-9,860-29,103 33.9%  
From Financial Activity Rs m6,64423,158 28.7%  
Net Cashflow Rs m-1,5357,556 -20.3%  

Share Holding

Indian Promoters % 32.3 74.8 43.2%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 4.6 8.3 55.4%  
FIIs % 3.3 5.9 55.9%  
ADR/GDR % 4.6 0.0 -  
Free float % 55.3 11.0 502.7%  
Shareholders   84,811 44,069 192.5%  
Pledged promoter(s) holding % 54.9 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ORCHID PHARMA LTD With:   ELDER PHARMA  TTK HEALTHCARE  AJANTA PHARMA  GSK PHARMA  ALEMBIC PHARMA  

Compare ORCHID PHARMA LTD With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Opens Marginally Higher; ONGC Rallies 6.3%(09:30 am)

Asian stock markets traded on a mixed note in morning trade as market participants kept an eye on political developments in the U.S. after a government shutdown began last week.

Related Views on News

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

More Views on News

Most Popular

Retail Investors or Chickens Waiting to Get Slaughtered in the Stock Market?(Vivek Kaul's Diary)

Jan 9, 2018

The price to earnings ratio of the Nifty 50 is very close to all-time high levels.

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Did GST and Notebandi Help? Sherlock Holmes Finds Out...(The 5 Minute Wrapup)

Jan 13, 2018

Discussions with my cousin helped me understand the situation on Ground Zero - after the demonetization and GST upheaval. Here's what that means for listed companies...

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

Nirvana denied: Has Value Failed?(The Honest Truth)

Jan 13, 2018

Should investors choose growth over value this year?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ORCHID PHARMA LTD SHARE PRICE


Jan 22, 2018 11:41 AM

TRACK ORCHID PHARMA LTD

  • Track your investment in ORCHID PHARMA LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ORCHID PHARMA LTD

ORCHID PHARMA LTD 8-QTR ANALYSIS

COMPARE ORCHID PHARMA LTD WITH

MARKET STATS